HC Wainwright Forecasts Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Envoy Medical in a report released on Tuesday, March 31st. HC Wainwright analyst Y. Chen expects that the company will earn ($0.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.00.

Envoy Medical Stock Performance

NASDAQ COCH opened at $0.71 on Thursday. The business’s 50 day moving average price is $0.68 and its 200-day moving average price is $0.76. Envoy Medical has a fifty-two week low of $0.36 and a fifty-two week high of $1.91. The company has a market cap of $54.20 million, a P/E ratio of -0.58 and a beta of 2.08.

Envoy Medical (NASDAQ:COCH) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million.

Institutional Trading of Envoy Medical

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in shares of Envoy Medical by 111.3% in the fourth quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after purchasing an additional 51,813 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Envoy Medical in the 3rd quarter valued at about $60,000. Finally, Focus Partners Wealth purchased a new position in shares of Envoy Medical during the first quarter worth approximately $276,000. 8.59% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Envoy Medical news, CFO Robert Potashnick purchased 212,500 shares of Envoy Medical stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $85,000.00. Following the completion of the acquisition, the chief financial officer owned 212,500 shares in the company, valued at $85,000. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mona Chetan Patel purchased 312,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average cost of $0.40 per share, with a total value of $125,000.00. Following the completion of the purchase, the director directly owned 332,500 shares in the company, valued at $133,000. The trade was a 1,562.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 20,433,650 shares of company stock valued at $8,173,460. 5.70% of the stock is currently owned by corporate insiders.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.